VYNE Therapeutics(VYNE) Stock Price Today

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Vyne Therapeutics To Present At Autoimmune & Inflammatory Disease Virtual Conference March 27
BenzingaMar 20 08:04 ET
VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
GlobeNewswireMar 20 08:00 ET
Why Paymentus Holdings Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket
BenzingaMar 11 06:55 ET
VYNE Therapeutics Reports Progress in Clinical Trials
TipRanksMar 7 22:57 ET
Analysts Offer Insights on Healthcare Companies: VYNE Therapeutics (VYNE), Lexicon Pharmaceuticals (LXRX) and Xtant Medical Holdings (XTNT)
TipRanksMar 7 06:51 ET · Ratings
VYNE Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag
Yahoo FinanceMar 7 05:15 ET

Comments

72271295

Jan 6 20:59

why it has been stopped?

Teddy123

Jan 6 20:51

Positive clinical and market research

$VYNE Therapeutics (VYNE.US)$
VYNE Therapeutics Completes Phase 2b Trial Enrollment for Novel Vitiligo Treatment VYN201

Trytosaveabit

Jan 6 20:34

Update

$VYNE Therapeutics (VYNE.US)$ Reuters· 3 mins ago
Vyne Therapeutics Completes Enrollment in Phase 2B Trial Evaluating Vyn201 for the Treatment of Nonsegmental Vitiligo

Jaguar8

Jan 6 20:30

NEWS

$VYNE Therapeutics (VYNE.US)$
VYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluating VYN201 for the Treatment of Nonsegmental Vitiligo
Monday, 6th January at 7:30 am
• Once-daily VYN201 gel being evaluated in subjects with nonsegmental vitiligo
• Top-line data from the 24-week double-blind portion of the trial expected in mid-2025
• "Repibresib" approved as the non-proprietary name for VYN201 by USAN
BRIDGEWATER, N.J., Jan. 06, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. ...

1

Jaguar8

Dec 23, 2024 20:37

NEWE

$VYNE Therapeutics (VYNE.US)$
VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor
VYNE Therapeutics announced positive results from the multiple ascending dose (MAD) portion of its Phase 1a trial for VYN202, a novel BD2-selective BET inhibitor. The study demonstrated a favorable safety and tolerability profilewith no serious adverse events or drug-related issues historically associated with earlier BET inhibitors.
Key findings includ...

1

VYNE VYNE Therapeutics

Trade Overview

Capital Trend

News

Comments